23andMe (NASDAQ: ME) is a consumer genetics and research company operating in the healthcare and biotechnology sectors. It offers a deoxyribonucleic acid (DNA) testing services that provide insights into ancestry and health predispositions, helping individuals understand their genetic makeup. Its services are primarily used by individuals seeking to learn more about their genetic health risks and ancestry. The company was founded in 2006 and is based in Sunnyvale, California.
23andMe's Products & Differentiators
Ancestry +Traits Service
Traces your genetic heritage and creates your genetic family tree. This product also gives your likelihood of expressing 30+ genetic traits like you fear of heights or if you are more likely to prefer chocolate or vanilla ice cream. You can find details on the product at https://www.23andme.com/
Research containing 23andMe
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned 23andMe in 11 CB Insights research briefs, most recently on Aug 9, 2023.
Expert Collections containing 23andMe
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
23andMe is included in 6 Expert Collections, including Conference Exhibitors.
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Tech IPO Pipeline
Digital Health 150
The most promising digital health startups transforming the healthcare industry
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
60+ underwriting data companies addressing 7 technology priorities, from wearables to genomic screening tools, that life insurance companies face.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
23andMe has filed 132 patents.
Computational complexity theory, Family, Kinship and descent, Human evolution, Genetic genealogy
Computational complexity theory, Family, Kinship and descent, Human evolution, Genetic genealogy
Latest 23andMe News
Nov 27, 2023
SHARE: The holidays are for family. And for 23andMe, the hope is that all the time spent with family will get people thinking about how genetics influence health. 23andMe is mostly known for its ancestry services, but a new campaign aims to raise awareness about its health services, which can identify potential risks based on genetic makeup. The campaign features testimonials in which users discovered previously undiagnosed health issues or genetic predispositions through the company’s health services. It will run on linear TV, CTV and YouTube throughout the holiday season and into next year. Other than some initial tests that ran during the summer, this campaign represents 23andMe’s first real foray into CTV advertising, said CMO Jon Ward. The main goal of this campaign is to drive purchase intent, Ward said. A new audience To reach new users, 23andMe and agency of record Deutsch LA built an entirely new audience pool to target. The companies conducted two surveys polling users about their interest in DNA health screenings and other health products, such as fitness trackers. Based on the survey results, 23andMe created audience profiles and used those profiles to target lookalike audiences for its TV and CTV ad buys. “We broke the world into seven segments, and we identified three segments that we thought were appealing for DNA health,” Ward said. The three segments were comprised of consumers who are interested in health and technology and those who buy health-related products like Fitbits. The company did not use any of its own first-party data derived from its existing user base to create the target audience for this campaign, Ward said, because it was only interested in targeting new users. The decision to not use first-party data also ensured that no existing user data would leak as a result of being exchanged by partners in the programmatic supply chain – a positive takeaway for a company that has faced criticisms over data security after past leaks, such as an incident in October in which hackers accessed user profiles. 23andMe is purchasing video inventory for this campaign through Tatari’s TV advertising platform. Tatari, which has worked with 23andMe on past video campaigns for its Lemonaid Health pharmacy service, also handled campaign optimization. The linear TV portion of the campaign includes only direct deals, but the CTV portion is being purchased programmatically. Meanwhile, the YouTube inventory is bought through Google’s Performance Max. None of the inventory is being purchased through a direct connection to an SSP. TV and CTV pros and cons 23andMe has put together at least four ad spots for the campaign, but it’s starting by running just two. The ads feature user-generated content, and were created by agency Los York. Tatari is applying hourly and daily frequency capping to ensure the spots aren’t repetitive. For linear TV, 23andMe wanted to capitalize on two past trends: its products perform well among consumers buying holiday gifts and the consideration cycle for holiday purchases tends to be shorter than other times of the year. “There’s a specific dispersion of media spending based on when we think people are going to purchase,” he said. “Holidays are a totally different beast, so we’re trying to align the investment with an almost immediate return.” 23andMe and its agency identified specific placements for its audiences – generally in sports and other event-driven media, Ward said. They then worked with Tatari to target similar programming and other possible placements on CTV. Despite the buzz around CTV, linear still has many benefits, Ward said. Namely, buyers can be confident they’re getting the inventory and audiences they want and will be placed alongside other high-quality advertisers. However, while it’s harder to target specific shows on CTV, the channel returns more data, he added. “We can see sales come through and match those IP addresses to where spots ran” to aid in attribution and optimization, he said. Plus, CTV inventory tends to be much less expensive than the premium linear inventory 23andMe usually buys, he added. CTV’s post-cookie role Although this is 23andMe’s first real CTV campaign, Ward sees the channel becoming much more important with the ongoing deprecation of third-party cookies, which aren’t really used in CTV. 23andMe is aware where it’s reliant on third-party cookies and has plans to decrease its use of the tech. Online display ads – which are heavily dependent on third-party cookies – aren’t a large part of 23andMe’s budget to begin with, Ward said. And the company is testing using first-party data for its retargeting display campaigns. For attribution, 23andMe prefers to use post-purchase surveys, regression tests and incrementality testing to gauge performance instead of using third-party cookies to measure the success of campaigns. “We’re going to be doing less with third-party cookies over time,” Ward said, “and we’re going to continue down the path of video and, specifically, television.”
23andMe Frequently Asked Questions (FAQ)
When was 23andMe founded?
23andMe was founded in 2006.
Where is 23andMe's headquarters?
23andMe's headquarters is located at 223 North Mathilda Avenue, Sunnyvale.
What is 23andMe's latest funding round?
23andMe's latest funding round is Corporate Minority - P2P.
How much did 23andMe raise?
23andMe raised a total of $877.69M.
Who are the investors of 23andMe?
Investors of 23andMe include GSK, Casdin Capital, Fidelity Investments, Altimeter Capital, Foresite Capital and 32 more.
Who are 23andMe's competitors?
Competitors of 23andMe include Viome, Genomelink, Geneticure, Sano, MedySapiens and 7 more.
What products does 23andMe offer?
23andMe's products include Ancestry +Traits Service and 3 more.
Compare 23andMe to Competitors
Color operates as a healthcare technology company democratizing access to genetic information. It offers color tests for patients to detect hereditary cancers such as breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. Color was formerly known as Color Global. It was founded in 2014 and is based in Burlingame, California.
LetsGetChecked is a virtual care company that operates in the healthcare sector. The company provides telehealth services, pharmacy services, and at-home laboratory tests for a variety of health conditions. These services are primarily aimed at individuals seeking to manage their health from home. It was founded in 2015 and is based in Dublin, Ireland.
Everly Health provides an electronic commerce platform. It enables customers to buy a variety of test kits online, collect their samples at home, and get results without visiting a lab or doctor's office. It offers various at-home lab tests such as sexual health, thyroid, metabolism, men's health, and more. The company was formerly known as Everly Well. It was founded in 2015 and is based in Austin, Texas.
Ancestry focuses on family history and consumer genomics. The company offers services to allow individuals to discover their family history and gain insights from their deoxyribonucleic acid (DNA), such as their ethnicity and personal traits. It primarily serves individuals interested in personal discovery and understanding their family history. It was formerly known as The Generations Network. It was founded in 1983 and is based in Lehi, Utah.
Helix works as a population genomics company operating in the healthcare and life sciences sectors. The company provides solutions that enable health systems, public health organizations, and life science companies to integrate genomic data into patient care and public health decision-making. Its primary customers are health systems, public health entities, and life science companies. It was founded in 2015 and is based in San Mateo, California.
OmeCare provides physicians and their patients with genetic information to improve or maintain health and wellness. The company's mobile health applications merge artificial intelligence and deep learning with personal genetic information that provides personalized health and wellness guidance.